mynth
04/2026100%

Céfiméca acquired by Oury Medical

FRANCE Life Sciences / Medical Devices / Implants & Prosthetics REV €5–25M

Context

The acquisition of Céfiméca by Oury Medical represents a strategic consolidation within the French orthopedic and spinal medical device market. This transaction is the fifth build-up operation completed by Oury Medical in three years, following a platform strategy initiated by its lead investors. The primary rationale behind the deal is the creation of a comprehensive "One-Stop-Shop" offering for global orthopedic clients, combining Céfiméca’s specialized expertise in precision implants with Oury Medical’s established strength in surgical instrumentation. By integrating Céfiméca’s two production sites, the enlarged group reaches a critical mass of five manufacturing facilities and over 400 employees (combined), significantly enhancing its industrial capacity. The deal aims to improve market competitiveness by reducing lead times and offering a more integrated value chain, transitioning from a traditional supplier role to a strategic partnership model. The integration of Céfiméca’s high-value implant range specifically addresses the group's objective to master both the tools and the permanent devices used in joint and spinal procedures.

Céfiméca, which reported an EBITDA margin of [members only] in 2024, is valued in this transaction at an EV/EBITDA multiple of [members only].

-> Deep-dive in Healthcare & Pharma market trends

Target

Céfiméca is a specialized manufacturer of high-precision surgical instruments and orthopedic implants. Based in La Talaudière, near Saint-Étienne, the company supports a broad client base from the prototyping phase through to serial production for various joint applications. Its technical expertise centers on precision mechanics, allowing for the creation of both standard and custom instrumentation used in orthopedic and spinal surgeries. The business model is built upon high quality standards and regulatory compliance, maintaining two production sites to ensure industrial reliability. By focusing on the convergence of complex mechanical engineering and medical requirements, Céfiméca serves as a critical supplier for major global players in the healthcare sector, particularly those requiring specialized implant capabilities and technical depth in spinal surgery solutions.

Ent. Value

[members only]

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2024
€5–25M
€0–5M
€0–5M
2023
€5–25M
€0–5M
€0–5M

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
06/2026MOTION EQUITY PARTNERSPOLARISFRANCENutrition & Dietary Supplements
05/2026STRYKERAMPLITUDE VASCULAR SYSTEMSUNITED STATESMedical Devices
04/2026ASTORGTHERMO FISHER MICROBIOLOGYUNITED STATESDiagnostic Equipment
04/2026HALMASURGISTARUNITED STATESMedical Devices
04/2026AMERICAN INDUSTRIAL PARTNERS AIPAVANOS MEDICALUNITED STATESMedical Consumables
04/2026GILEAD SCIENCESARCELLXUNITED STATESR&D Biotech
04/2026FINE FOODS & PHARMACEUTICALSSOFARITALYCDMO
04/2026FOR TALENTS / UI INVESTISSEMENT / GENEONEFTYS PHARMAFRANCEAnimal Health
04/2026DEVYSER DIAGNOSTICSCYBERGENESWEDENDiagnostic Equipment
04/2026REVENIO GROUP CORPORATIONVISIONIX INTERNATIONALFRANCEDiagnostic Equipment

REFERENCES

Revenue range: REV €5–25M

EBITDA range: €0–5M

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Céfiméca by Oury Medical are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: céfiméca

FAQ

What transaction does this page cover?

This page covers Oury Medical’s acquisition of 100% of Céfiméca, a French company specialised in Medical Devices, in 2026.

What were Céfiméca’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Céfiméca generated annual revenue estimated in the €5–25M range and EBITDA in the €0–5M bracket (FY 2024). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction data and operational intelligence were compiled from independent financial press reporting by specialized M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.